Discover how deucravacitinib, a first‑in‑class oral TYK2 inhibitor, delivers biologic‑like efficacy in plaque psoriasis with once‑daily dosing, high selectivity, and a potentially improved safety profile compared with traditional JAK inhibitors.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs